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Abstract
Background: Group B Streptococcus (GBS) causes severe infections in very young infants and
invasive disease in pregnant women and adults with underlying medical conditions. GBS
pathogenicity varies between and within serotypes, with considerable variation in genetic content
between strains. Three proteins, Rib encoded by rib, and alpha and beta C proteins encoded by bca
and bac, respectively, have been suggested as potential vaccine candidates for GBS. It is not known,
however, whether these genes occur more frequently in invasive versus colonizing GBS strains.
Methods: We screened 162 invasive and 338 colonizing GBS strains from different collections
using dot blot hybridization to assess the frequency of bca, bac and rib. All strains were defined by
serotyping for capsular type, and frequency differences were tested using the Chi square test.
Results: Genes encoding the beta C protein (bac) and Rib (rib) occurred at similar frequencies
among invasive and colonizing isolates, bac (20% vs. 23%), and rib (28% vs. 20%), while the alpha
(bca) C protein was more frequently found in colonizing strains (46%) vs, invasive (29%). Invasive
strains were associated with specific serotype/gene combinations.
Conclusion: Novel virulence factors must be identified to better understand GBS disease.
Background
Group B Streptococcus (GBS) causes sepsis and meningitis
in young infants, febrile complications in pregnant
women and invasive disease in adults with underlying
medical conditions [1]. Capsular polysaccharide, which
defines GBS serotype, is the primary virulence factor
found in most GBS strains, and different serotypes con-
tribute to disease in different populations. For example,
30% of GBS disease in non-pregnant adults is caused by
serotype V [2], while serotype III causes more than 70% of
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disease [3]. Vaccines currently under development target
the most prevalent GBS serotypes [4].
Other than the polysaccharide capsule, little is known
about other GBS components important in pathogenesis.
Many putative virulence factors and genes have been iden-
tified recently (for a review see [5]), though most are
either present in all GBS strains, or are lacking sufficient
data to pinpoint their role in the pathogenic process.
Three proteins, however, have been studied extensively
and were recommended as potential GBS vaccine candi-
dates [6-8]. These include the protein Rib [7] encoded by
rib [9], and the alpha [10] and beta [10] C proteins
encoded by bca [11] and bac [12], respectively. All three
proteins trigger antibody production that offers protec-
tion from GBS infection in animal models [7,8,13],
though the frequency of these proteins and the genes that
encode them varies by disease status [14-19] as well as
serotype. For example, Rib has been found predominantly
in serotype III strains [7]. To date, large, population-based
studies comparing the frequencies of genes encoding the
Rib, alpha and beta C proteins among invasive and colo-
nizing isolates have been limited.
Methods
We describe the frequency of genes encoding three viru-
lence factors among five GBS strain collections including
invasive (n = 162) and colonizing (n = 338) isolates
(Table 1); invasive disease status was not known for 29
strains. All isolates tested were obtained with the approval
of an appropriate institutional ethics committee. Invasive
isolates originated from the blood or cerebrospinal fluid
(CSF) of newborns <7 days of age (n = 100), the urine of
college students (n = 4) [20,21] and pregnant women pre-
senting to the University of Michigan Medical Center
(UMMC) for prenatal care associated with GBS isolation
from the urine (n = 58), and the placenta following deliv-
ery (n = 5) [22]. Newborn isolates, described by Zaleznik
et al. [23] (n = 65), were collected between 1993 and
1996, while the remainder (n = 35) came from the same
Houston hospitals between 1997 and 2000. Colonizing
GBS isolates were from the anal orifice or urine of healthy
male (n = 58) college students, the anal orifice, vagina,
cervix or urine or healthy female (n = 86) college students
[21], pregnant women from UMMC (n = 49) [22], and
sexually active college women with a urinary tract infec-
tion not caused by GBS (n = 102) and their most recent
male sex partner (n = 43) [20]. Among colonizing isolates,
17 (6.9%) were from individuals colonized with multiple
isolates in multiple sites; the dot blot profile was deter-
mined only for those isolates that were unique by pulsed-
field gel electrophoresis (PFGE) as described previously
[20,21,24].
Serotyping using hyperimmune rabbit antisera to GBS
polysaccharide types Ia, Ib, and II-VIII was performed as
described previously [20,21]. We amplified DNA for
genes encoding bca, bac and rib using PCR (Table 2). Con-
trol strain A909 was used to amplify bca and bac [25],
while BM110 was used for rib [9]. PCR DNA was purified
and fluorescein-labeled as described previously [26].
DNA was isolated using a modified E. coli protocol [27] in
which cells were lysed overnight. Dot blot hybridization
and subsequent analyses were performed as described pre-
viously [26,28] with two negative and positive controls
per membrane. The signal intensity of each dot was
reported as a percentage of the positive control present on
each membrane in ImageQuant (Molecular Dynamics,
CA). Percentages were corrected for the background signal
of the negative controls and graphed. The x-axis repre-
sented values from one membrane and the y-axis con-
sisted of values from the duplicate membrane. A cutoff
was established based on each graph distribution [26].
Isolates within the intermediate range were repeated.
Sixty-eight hybridizations yielded equivocal results
despite repeated probing, and thus, were confirmed for
the presence or absence of each gene by PCR and sequenc-
ing using the same primers described in Table 2. Eleven
remained equivocal following PCR and were excluded
from the analyses.
Chi square tests were used to assess differences in gene fre-
quencies by collection and serotype. SAS was used for all
statistical analyses [29].
Results
Across GBS strain collections, the bca gene occurred most
frequently, followed by rib and bac (Table 3). bca and bac
occurred most frequently among colonizing isolates from
college students (Collections 1, 2, and 4, Table 1), while
the frequency of rib was similar across collections. Because
gene frequency varies by capsular serotype, we described
the frequency of each gene by serotype (Figure 1). When
assessing the frequencies among invasive versus coloniz-
ing isolates, only isolates from newborns with GBS dis-
ease (n = 100) were considered invasive, while colonizing
isolates consisted of those isolates known to not cause a
UTI and those that were isolated during pregnancy as part
of routine GBS screening (n = 360). In this analysis, rib
occurred slightly more frequently among invasive versus
colonizing isolates (p = .09) (Table 4), while both bac (p
= .55) and bca (p = .002) occurred less frequently in the
invasive strains.
After stratifying by serotype, invasive versus colonizing
capsular serotype Ia strains were significantly less likely to
have bca (p = .002), while Ib invasive strains were more
likely to have bca (p = .03) (Table 4). Invasive versus col-Page 2 of 7
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likely to have both rib (p = .09) and bac (p = .06), and less
likely to have bca (p = .09).
Because a previous study also indicated that rib occurs
more frequently in invasive isolates [7], we further exam-
ined its frequency by colonization site. Among invasive
Table 2: PCR primers used to amplify DNA regions specific to the genes encoding the alpha (bca) and beta (bac) C proteins, and the 
protein Rib (rib).*
Gene Forward primer Reverse primer Reference Size Annealing temperature Extension time
bca 5'-TAACAGTTATGATACTTCACAGAC-3' [11] 535 bp 68°C 33 sec
5-'ACGACTTTCTTCCGTCCACTTAGG-3'
bac 5'-CTATTTTTGATATTGACAATGCAA-3' [12] 592 bp 60°C 36 sec
5'-GTCGTTACTTCCTTGAGATGTAAC-3'
rib 5'-CAGGAAGTGCTGTTACGTTAAAC-3' [9] 369 bp 58°C 22 sec
5'-CGTCCCATTTAGGGTCTTCC-3'
* PCR conditions for each reaction included a five minute denaturation step at 95°C, and 30 cycles of the following: 35 second denaturation, 40 
second annealing and varying extension times. The extension temperature was 73°C for all reactions.
Table 1: Number of group B streptococcal isolates (n = 529) screened via dot blot hybridization and characteristics of each 
collection*.
GBS Collection Isolation source Culture date Age range Race/ethnicity Number of strains
1a. Sexually active college 
women with UTI receiving care 
from a Student Health Services at 
the University of Michigan (UM) 
[22].
urine, anal orifice, 
vaginal
Sept. 1996 to April 
1999
18–30 White (76%), Non-
White (24%)
Colonizing (n = 102), 
Invasive† (n = 2)
1b. Most recent male sex 
partner of women with UTI 
receiving care from the Student 
Health Services at UM [22].
urine, anal orifice Sept. 1996 to April 
1999
18–35 White (71%), Non-
White (29%)
Colonizing (n = 43), 
Invasive† (n = 0)
2a. Sexually active college 
women without UTI presenting 
to the Student Health Services at 
UM [22].
urine, anal orifice, 
vaginal
Sept. 1996 to April 
1999
18–28 White (80%), Non-
White (20%)
Colonizing (n = 57), 
Invasive† (n = 0)
2b. Most recent male sex 
partner of women without UTI 
presenting to the Student Health 
Services at UM [22].
urine, anal orifice Sept. 1996 to April 
1999
19–33 White (73%), Non-
White (27%)
Colonizing (n = 35), 
Invasive† (n = 0)
3. Newborns with early onset 
disease from hospitals affiliated 
with Baylor College of Medicine 
[19].
blood, CSF 1993 to 2000 < 7 days Hispanic (56%), 
African American 
(24%), Caucasian 
(16%), Asian (4%)
Colonizing (n = 0), 
Invasive† (n = 100)
4a. Random sample of college 
aged women from the UM 
community [21]
urine, anal orifice, 
vaginal
Sept. to Nov. 1998 17–49 Caucasian (65%), 
Asian (16%), African 
American (10%), 
Hispanic (5%), Other 
(5%)
Colonizing (n = 29), 
Invasive† (n = 1)
4b. Random sample of college 
aged men from the UM 
community [21]
urine, anal orifice Sept. to Nov. 1998 19–45 Caucasian (60%), 
Asian (28%), African 
American (4%), 
Hispanic (3%), Other 
(4%)
Colonizing (n = 23), 
Invasive† (n = 1)
5. Pregnant women presenting at 
the UM Medical Center for 
prenatal care [34].
urine, rectal, vaginal, 
placental
Aug. 1999 to Mar. 
2000
16–42 Caucasian (67%), 
African American 
(18%), Other (7%), 
Unknown (9%)
Colonizing (n = 49), 
Invasive† (n = 53), 
Unknown (n = 29)
* Seventeen individuals (7 from collection 1a, 4 from collection 2a, 3 from collection 2b, and 3 from collection 4b) were colonized with two 
genetically distinct strains, as determined by pulsed-field gel electrophoresis.
†Invasive isolates originated from the blood or cerebrospinal fluid of newborns <7 days of age, the urine of adults at ≥100,000 cfu/ml, pregnant 
women presenting for prenatal care associated with GBS isolation from the urine, and the placenta following delivery. Colonizing GBS were from 
the anal orifice, lower vagina, cervix or urine of healthy individuals, and sexually active college women with a urinary tract infection not caused by 
GBS.Page 3 of 7
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cerebrospinal fluid (CSF) compared to blood was 3.6
higher when rib [95% CI: (0.86, 15.44), p = .04], and 4.1
times higher when bac [95% CI: (0.92, 17.91), p = .03]
were present. There was no association with bca. Because
rib occurred in 92% of capsular serotype III isolates and
was found infrequently in other serotypes, and type III
occurred more frequently among infants with invasive
disease, it is likely that the association with CSF is attrib-
utable to confounding. When we examined the coloniza-
tion site by serotype among rib positive strains, 26% of
serotype III and no serotype II strains (the only other sero-
type with rib) were isolated from the CSF. By contrast,
among isolates without rib, 6%, 10% and 17% of serotype
Ia, II and Ib strains, respectively, were isolated from the
CSF. In a similar analysis of among bac positive strains,
50% of serotype III and 18% of serotype Ib, but no sero-
type II or V strains were isolated from the CSF. When the
analysis was restricted to serotype III strains, rib was not
associated with CSF isolation, but bac was (OR: 4.7, 95%
CI: 0.43, 60.74), although the sample size was too small
to achieve statistical significance (p = .12).
The bca and bac genes frequently occurred together; 74
strains contained both genes among 324 strains with at
least one gene (p < .0001). rib was significantly less likely
to occur with either bca (11/333, p < .0001) or bac (14/
224, p = .01). These relationships were similar when strat-
ified by isolate type with a few exceptions. Among the 14
strains with rib and bac, 8 (57%) were invasive (p = .002);
7 of these 8 were from newborns and 6 of the 7 newborn
strains were serotype III. Strains with both bca and rib
together were more frequent in colonizing versus invasive
strains (p = .03) as were strains with both bca and bac (p =
.10).
Discussion
Based on the suggestion that the alpha and beta C pro-
teins and protein Rib protein serve as potential vaccine
GBS candidates either in glycoconjugates or alone [6-8], it
was estimated in 1988, before the emergence of serotype
V GBS, that a vaccine containing the alpha C protein and
a serotype III component would prevent at least 90% of
GBS cases [30]. Although we did not find these three
genes significantly more frequently in invasive versus col-
onizing GBS strains, bac was found more frequently
among isolates from CSF than blood in invasive serotype
Serotype distribution by genesFigure 1
The number of strains with genes encoding the alpha (bca) 
and beta (bac) C proteins and the protein Rib (rib) by sero-
types Ia (n = 115), Ib (n = 60), II (n = 67), III (n = 84*), IV (n = 
2), V (n = 105*), VI (n = 7*), VIII (n = 1), and nontypeable 
(NT) (n = 53). The sample represents the maximum number 
of isolates tested, which varied slightly by gene; serotyping 
data was not available for 35 strains.
Table 3: The frequency of genes encoding the alpha (bca) and beta (bac) C protein, and the protein Rib (rib) among various GBS 
populations.
alpha antigen (bca) ‡ beta antigen (bac) ‡ Rib protein (rib)
GBS Collection Number 
screened
n (%) Number 
screened
n (%) Number 
screened
n (%)
1. Sexually active college women with UTI and 
sex partner†
145 63 (43) 147 26 (18) 146 33 (23)
2. Sexually active college women without UTI 
and their sex partner
93 58 (62) 93 26 (28) 93 17 (18)
3. Infected newborns < 7 days of age 100 29 (29) 100 20 (20) 100 28 (28)
4. Random sample of college students† 53 25 (47) 53 18 (34) 53 13 (25)
5. Pregnant women 135 41 (30) 131 18 (14) 134 27 (20)
Total 526 216 (41) 524 108 (21) 526 118 (22)
Note: n (%) represents the number of participants with the respective gene in each population; the number screened varies slightly by gene and 
population because a result could not be obtained for 4 strains tested for rib and bca, and 6 strains tested for bac despite repeated testing.
†There was no difference in gene frequency by gender so the results were combined for presentation.
‡Using the Chi-square test, a significant difference at the p = .05 significance level was observed between bca frequencies in collection 2 versus 3 (p 
< .0001), 5 (p < .0001) and 1 (p = .004); and between bac frequencies in collection 2 versus 5 (p = .008).Page 4 of 7
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ease severity.
Although we detected differences in the frequency of spe-
cific genes, it is possible that the encoded proteins are dif-
ferentially expressed [31,32] and thus, differences in
pathogenicity could be attributable to differences in gene
expression. A prior study demonstrated that protein Rib
[7] was present in more invasive versus colonizing sero-
type III strains. In this study, invasive strains were more
likely to have rib (p = .09), but the association was only
marginally significant. A similar observation was found
for bac (p = .06), which is consistent with a prior report
[18]. However, we cannot exclude the possibility that the
differences in collection date and geographic location are
responsible for this result. Further, and possibly more
important, the isolates assessed may contain other
unknown virulence characteristics important to invasion,
as the virulence of GBS is probably attributable to multi-
ple genes. Our collections of invasive isolates were limited
to those from newborns, pregnant women and healthy
young women. It is possible that these virulence genes
might have different impacts in other susceptible popula-
tions, such as the elderly or those with underlying chronic
disease.
Conclusion
We observed only a marginally significant difference in
bac, bca and rib frequency between invasive and coloniz-
ing serotype III strains, thereby raising the possibility that
other genes explain the association of serotype III with
invasive disease. It is noteworthy, however, that both rib
and bac were found more frequently in the newborn sero-
type III isolates, while bca was found less frequently.
Because various genotyping methods, such as multilocus
sequence typing (MLST), have distinguished between col-
onizing and invasive strains, [33] this warrants further
study. Using the framework provided by MLST, for exam-
ple, may allow us to assess the distribution of these genes
by sequence types found to be associated with invasive-
ness. In addition, it is clear that GBS disease pathogenesis
is complex, thus novel virulence genes need to be identi-
fied and evaluated to understand their role in the patho-
genic process, and provide additional vaccine targets.
Recently published GBS DNA sequences [34-36] will facil-
itate the identification of these novel factors.
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